NON-HODGKIN'S LYMPHOMA

This study is testing whether a combination of two drugs, copanlisib and rituximab, can effectively control follicular lymphoma in people who have not yet received treatment. The goal is to see if this drug duo can lead to deep and lasting remissions without using traditional che…

This early-stage trial is testing the safety of a two-part treatment for aggressive B-cell non-Hodgkin lymphoma that has returned or not responded to other therapies. First, patients receive high-dose chemotherapy and a transplant of their own blood stem cells. Then, they receive…

This early-phase study tests a new cell therapy for patients whose Hodgkin's or Non-Hodgkin's lymphoma has returned. Doctors take a patient's own immune cells, genetically modify them in a lab to better recognize and attack cancer cells, and then infuse them back. The main goal i…

This study collects a person's own white blood cells to potentially make a future cancer treatment called CAR-T cell therapy. It is for children and adults (ages 3-65) with certain types of leukemia or lymphoma that have not been cured by standard treatments. The collected cells …

This study allows patients already receiving venetoclax in other trials to continue treatment if they are benefiting and tolerating it well. The main goal is to collect long-term safety information by tracking any side effects. It includes about 165 patients with various blood ca…

This study is testing whether two drugs, palifermin and leuprolide acetate, can help a patient's immune system recover more quickly after receiving a stem cell transplant from a donor. The transplant is for patients with blood cancers like leukemia or lymphoma. Researchers want t…

This is a first-in-human study to test the safety of a new type of 'off-the-shelf' immune cell therapy called SC262. It is for adults with non-Hodgkin's lymphoma whose cancer has come back or stopped responding to treatment, including a prior CAR-T therapy. The main goal is to fi…

This early-phase study is testing the safety of a new cell therapy for patients whose blood cancer (like leukemia or lymphoma) has come back after a stem cell transplant from a donor. Doctors take immune cells (T cells) from the donor, genetically modify them in a lab to better r…

This study is testing how well two targeted drugs, obinutuzumab and ibrutinib, work together as the first treatment for people with certain slow-growing types of non-Hodgkin's lymphoma. The goal is to control the cancer by stopping cancer cells from growing and spreading, potenti…

This early study aims to understand how a new drug called PUH71 moves through the body and gathers in tumors when given in very small amounts. Researchers will use PET scans to track the drug in patients with various cancers, including lymphoma, myeloma, and solid tumors. The res…